964. Impact of Doxycycline as Malaria Prophylaxis on Risk of Influenza Like Illness among International Travelers
Session: Oral Abstract Session: Adventures with Globally Acquired Infections
Friday, October 5, 2018: 11:00 AM
Room: S 158

International travelers are often at risk for both influenza like illness (ILI) and malaria. Doxycycline is active against many pathogens causing ILI and is routinely used for malaria prophylaxis. We evaluated the incidence of and risk factors for ILI, and whether the choice of malaria prophylaxis was associated with ILI.


TravMil is a prospective observational study enrolling subjects presenting to 6 military travel clinics. We analyzed pre- and post- travel surveys from travelers to regions outside of the continental United States, Western or Northern Europe, Canada or New Zealand between 7/2010 and 8/2018. ILI was defined as subjective fever associated with either a sore throat or cough. Characteristics of trip and traveler and use of malaria prophylaxis were analyzed to determine association with development of ILI. Poisson regression models with robust error variance were used to estimate relative risk of ILI.


3227 travelers were enrolled: 62.1% male, median age of 39 (IQR 27, 59), median travel duration 19 days (IQR 12, 49). 32% traveled to Africa, 40% to Asia, and 27% to the Caribbean, Mexico, Central or South America. Military travel (46%) and vacation (40%) were most common reasons for travel. 20% took doxycycline for malaria prophylaxis, 50% other prophylaxis (89% atovaquone-proguanil), and 30% took none. 8.7% developed ILI. Compared to those on no or other prophylaxis, doxycycline was associated with decreased risk of ILI [RR 0.65 (0.43-0.99), p = 0.046], as was military travel [RR 0.30 (0.21-0.43), p< 0.01]. Increased risk of ILI was associated with female gender, [RR 1.57 (1.24-1.98), p < 0.01], travel to Asia [RR 1.37 (1.08-1.75), p=0.01], cruises [RR 2.21 (1.73-2.83), p<0.01], and longer duration of travel [RR 1.01 (1.00-1.01, p<0.01].


Use of doxycycline is associated with a decreased risk of ILI compared to taking no or other malaria prophylaxis. The reasons for this are unclear but may be related to anti-inflammatory effects, activity against bacterial respiratory pathogens, effects on disease transmission in closed populations (e.g. military deploying groups), or other unmeasured factors. With few proven strategies for decreasing ILI risk in travelers, these findings bear further investigation.

Kathryn Lago, DO1, Kalyani Telu, MS2, David R. Tribble, MD, DrPH3, Anuradha Ganesan, MD, MPH4, Anjali Kunz, MD5, Charla Geist, DO6, Jamie Fraser, MPH2, Indrani Mitra, MS2 and Heather Yun, MD, FIDSA7, (1)San Antonio Military Medical Center, Fort Sam Houston, TX, (2)Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, (3)Infectious Disease Clinical Research Program, Uniformed Services University, Bethesda, MD, (4)Preventive Medicine and Biostatistics, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, (5)Madigan Army Medical Center, Tacoma, WA, (6)Landstuhl Regional Medical Center, Landsthul, Germany, (7)Brooke Army Medical Center, JBSA Fort Sam Houston, TX


K. Lago, None

K. Telu, None

D. R. Tribble, None

A. Ganesan, None

A. Kunz, None

C. Geist, None

J. Fraser, None

I. Mitra, None

H. Yun, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.